MeSH term
Frequency | Condition_Probility | Research Support, Non-U.S. Gov't | 70 | 0.0 |
Aged | 7 | 0.0 |
Humans | 106 | 0.0 |
Time Factors | 8 | 0.0 |
Cells, Cultured | 28 | 0.0 |
Gene Expression | 2 | 0.0 |
Immunohistochemistry | 4 | 0.0 |
Lymph Nodes/pathology | 2 | 0.0 |
Lymphocytes/pathology | 2 | 2.0 |
Reed-Sternberg Cells/*metabolism | 2 | 16.0 |
Reverse Transcriptase Polymerase Chain Reaction | 15 | 0.0 |
Tumor Cells, Cultured | 10 | 0.0 |
Chemokines/*physiology | 3 | 9.0 |
Comparative Study | 12 | 0.0 |
Immune Tolerance/*immunology | 2 | 4.0 |
Ligands | 9 | 0.0 |
RANTES/*physiology | 2 | 33.0 |
Signal Transduction/*immunology | 2 | 0.0 |
Cell Line, Tumor | 8 | 0.0 |
Cell Movement/drug effects | 2 | 0.0 |
Chemokines, CC/*pharmacology | 3 | 14.0 |
Dose-Response Relationship, Drug | 5 | 0.0 |
Gene Expression Regulation/*drug effects | 2 | 0.0 |
RNA, Messenger/metabolism | 6 | 0.0 |
Receptors, CCR5/metabolism | 3 | 2.0 |
Receptors, CXCR4/metabolism | 3 | 1.0 |
Antigens, CD/analysis | 2 | 0.0 |
Binding Sites | 2 | 0.0 |
Chemokines/*metabolism | 3 | 5.0 |
Immunoenzyme Techniques | 4 | 0.0 |
Monocyte Chemoattractant Protein-1/metabolism | 2 | 3.0 |
RANTES/metabolism | 5 | 8.0 |
Animals | 28 | 0.0 |
Cell Line | 14 | 0.0 |
Hamsters | 5 | 0.0 |
Lung/virology | 2 | 22.0 |
Mice | 18 | 0.0 |
Mice, Inbred BALB C | 5 | 0.0 |
Female | 18 | 0.0 |
RNA, Messenger/genetics/metabolism | 4 | 0.0 |
Binding, Competitive | 5 | 0.0 |
Blood Platelets/*metabolism | 3 | 1.0 |
Calcium/metabolism | 6 | 0.0 |
Cell Adhesion/drug effects | 2 | 0.0 |
Flow Cytometry | 8 | 0.0 |
Receptors, Chemokine/*metabolism | 5 | 3.0 |
Recombinant Fusion Proteins/physiology | 2 | 0.0 |
Transfection | 4 | 0.0 |
Chemokines, CC/*metabolism | 2 | 3.0 |
RNA, Messenger/biosynthesis | 5 | 0.0 |
Dendritic Cells/cytology/*drug effects/immunology | 2 | 16.0 |
Antigens, CD/immunology | 2 | 0.0 |
Killer Cells, Natural/*immunology | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 22 | 0.0 |
Cell Movement/physiology | 3 | 1.0 |
In Vitro | 3 | 0.0 |
Macrophage Inflammatory Protein-1/pharmacology | 2 | 4.0 |
Models, Biological | 3 | 0.0 |
Monocyte Chemoattractant Protein-1/pharmacology | 2 | 9.0 |
RANTES/pharmacology | 2 | 3.0 |
Recombinant Proteins/pharmacology | 3 | 0.0 |
Adult | 14 | 0.0 |
Bronchoalveolar Lavage Fluid/cytology | 2 | 1.0 |
*Gene Expression Regulation | 2 | 0.0 |
Male | 18 | 0.0 |
Middle Aged | 13 | 0.0 |
Receptors, CCR5/*genetics | 2 | 1.0 |
Blotting, Northern | 2 | 0.0 |
Cell Division | 4 | 0.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Chemokines, CXC/*physiology | 2 | 5.0 |
Chemotaxis | 3 | 1.0 |
NF-kappa B/metabolism | 3 | 0.0 |
Promoter Regions (Genetics) | 4 | 0.0 |
Signal Transduction | 4 | 0.0 |
Inflammation Mediators/*metabolism | 2 | 3.0 |
Protein Binding | 5 | 0.0 |
Mice, Inbred C57BL | 5 | 0.0 |
Mice, Knockout | 3 | 0.0 |
Proteins/*metabolism | 2 | 0.0 |
Cell Adhesion Molecules/metabolism | 2 | 0.0 |
Cytokines/metabolism | 4 | 0.0 |
Receptors, Chemokine/metabolism | 4 | 3.0 |
Up-Regulation | 8 | 0.0 |
CHO Cells | 3 | 0.0 |
HIV-1/*metabolism | 2 | 0.0 |
Mutation | 3 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Structure-Activity Relationship | 3 | 0.0 |
Substrate Specificity | 2 | 0.0 |
Arthritis, Rheumatoid/*immunology | 3 | 1.0 |
Enzyme Activation | 2 | 0.0 |
Fibroblasts/metabolism | 3 | 0.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 3 | 0.0 |
Mitogen-Activated Protein Kinase 3 | 2 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 2 | 0.0 |
Chemokines, CXC/biosynthesis | 2 | 8.0 |
Interleukin-12/biosynthesis | 2 | 2.0 |
Macrophage Inflammatory Protein-1/biosynthesis | 2 | 10.0 |
RANTES/biosynthesis | 2 | 11.0 |
Thiazoles/pharmacology | 2 | 1.0 |
Dendritic Cells/*immunology | 2 | 0.0 |
Receptors, Chemokine/immunology | 3 | 9.0 |
Amino Acid Sequence | 4 | 0.0 |
Calcium Signaling/drug effects | 2 | 4.0 |
Chemotaxis/drug effects | 2 | 2.0 |
Down-Regulation/drug effects | 4 | 1.0 |
Molecular Sequence Data | 3 | 0.0 |
Receptors, CCR5/*metabolism | 3 | 2.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Catalysis | 2 | 0.0 |
Kinetics | 3 | 0.0 |
Lymphocytes, Tumor-Infiltrating/immunology | 2 | 5.0 |
Cell Differentiation/immunology | 2 | 0.0 |
Chemokines/*immunology | 3 | 15.0 |
Receptors, CCR5/immunology/metabolism | 2 | 18.0 |
Receptors, Chemokine/immunology/metabolism | 2 | 33.0 |
Chemokines, CC/metabolism | 4 | 9.0 |
Fetus | 3 | 0.0 |
Transforming Growth Factor beta/pharmacology | 2 | 0.0 |
Tumor Necrosis Factor-alpha/metabolism | 3 | 0.0 |
Cytokines/secretion | 2 | 2.0 |
Enzyme-Linked Immunosorbent Assay | 6 | 0.0 |
Phenotype | 2 | 0.0 |
Chemokines/biosynthesis | 3 | 7.0 |
Chemokines, CC/biosynthesis | 3 | 18.0 |
*Monocyte Chemoattractant Protein-1 | 2 | 40.0 |
Chemokines, CC/*biosynthesis/*genetics | 2 | 100.0 |
Genes, pX | 2 | 40.0 |
Human T-lymphotropic virus 1/*pathogenicity | 2 | 50.0 |
Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated/*genetics/*virology | 2 | 100.0 |
RNA/biosynthesis | 2 | 2.0 |
Transcription, Genetic | 4 | 0.0 |
Chemokines/metabolism | 3 | 4.0 |
Interferon Type II/metabolism | 3 | 1.0 |
Macrophages/metabolism | 2 | 0.0 |
Mice, Transgenic | 3 | 0.0 |
Spleen/cytology | 2 | 1.0 |
Interleukin-8/biosynthesis/genetics | 2 | 8.0 |
Quinolinic Acid/*pharmacology | 2 | 40.0 |
RANTES/biosynthesis/genetics | 2 | 33.0 |
Receptors, Chemokine/*genetics | 3 | 3.0 |
Up-Regulation/drug effects | 2 | 0.0 |
Chemokines, CC/genetics/*metabolism | 3 | 21.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Receptors, Chemokine/genetics/*metabolism | 2 | 4.0 |
Aged, 80 and over | 2 | 0.0 |
Phosphorylation | 3 | 0.0 |
Gene Expression Regulation/immunology | 2 | 1.0 |
Species Specificity | 2 | 0.0 |
Treatment Outcome | 2 | 0.0 |
Base Sequence | 2 | 0.0 |
Antiviral Agents/pharmacology | 2 | 3.0 |
Virus Replication/drug effects | 2 | 0.0 |
CD4 Lymphocyte Count | 2 | 0.0 |
Mycobacterium tuberculosis/immunology | 2 | 6.0 |
Glucocorticoids/pharmacology | 3 | 2.0 |
Immunoglobulin G/immunology | 2 | 0.0 |
Interleukin-10/pharmacology | 2 | 2.0 |
Lipopolysaccharides/pharmacology | 2 | 0.0 |
Lymphocyte Activation | 3 | 0.0 |
Microscopy, Immunoelectron | 2 | 0.0 |
Disease Models, Animal | 2 | 0.0 |
Chemokines/*biosynthesis | 2 | 6.0 |
Monocytes/metabolism | 4 | 1.0 |
Chronic Disease | 2 | 0.0 |
Macrophages/immunology/metabolism | 2 | 4.0 |
Monocytes/immunology/metabolism | 2 | 4.0 |
Th1 Cells/*immunology | 2 | 1.0 |
Intercellular Signaling Peptides and Proteins/biosynthesis | 2 | 8.0 |
Tumor Necrosis Factor-alpha/pharmacology | 3 | 0.0 |
RANTES/genetics/*metabolism | 3 | 50.0 |
Chemokines/*genetics | 2 | 9.0 |
Gene Frequency | 3 | 0.0 |
Chemokines/secretion | 2 | 15.0 |
Cell Adhesion Molecules/*immunology | 2 | 3.0 |
Cell Movement | 2 | 0.0 |
Receptors, Chemokine/*physiology | 2 | 4.0 |
Receptors, CCR5/genetics/*metabolism | 2 | 5.0 |
Receptors, CCR5/*physiology | 2 | 4.0 |
Anti-HIV Agents/*pharmacology | 3 | 2.0 |
Chemotaxis, Leukocyte/drug effects | 2 | 2.0 |
Statistics, Nonparametric | 2 | 0.0 |
Chemotaxis/physiology | 2 | 6.0 |
Signal Transduction/physiology | 2 | 0.0 |
Chemokines, CC/antagonists & inhibitors | 2 | 66.0 |
Virus Replication/*drug effects | 2 | 1.0 |
Cell Movement/*immunology | 2 | 2.0 |
Case-Control Studies | 2 | 0.0 |
Immune Tolerance | 2 | 0.0 |
Dimerization | 2 | 0.0 |
